Insulin reverses choriocarcinoma 5- fluorouracil resistance

References

• Cheung AN, Zhang HJ, Xue WC, et al. Pathogenesis of choriocarcinoma: clinical, genetic and stem cell perspectives. Future Oncol. 2009;5(2):217–231.
   PubMed Web of Science ®Google Scholar
• She Q, Cheng Z, El-Chaar D, et al. Intraplacental choriocarcinoma coexisting with fetomaternal hemorrhage: case report, chemotherapy management, and literature review. Medicine (Baltimore). 2018;97(14):e9977.
   PubMed Web of Science ®Google Scholar
• Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J reproductive med. 1994;39(3):155–162.
   PubMed Web of Science ®Google Scholar
• Hoffner L, Surti U. The genetics of gestational trophoblastic disease: a rare complication of pregnancy. Cancer Genet. 2012;205(3):63–77.
   PubMed Web of Science ®Google Scholar
• Allias F, Bolze P-A, Gaillot-Durand L, et al. Les maladies trophoblastiques gestationnelles. Ann Pathol. 2014;34(6):434–447.
   PubMed Web of Science ®Google Scholar
• Small W Jr., Lurain JR, Shetty RM, et al. Gestational trophoblastic disease metastatic to the brain. Radiology. 1996;200(1):277–280.
   PubMed Web of Science ®Google Scholar
• Tidy JA, Rustin GJ, Newlands ES, et al. Presentation and management of choriocarcinoma after nonmolar pregnancy. Br J Obstet Gynaecol. 1995;102(9):715–719.
   PubMedGoogle Scholar
• Yang C, Lim W, Bazer FW, et al. Myricetin suppresses invasion and promotes cell death in human placental choriocarcinoma cells through induction of oxidative stress. Cancer Lett. 2017;399:10–19.
   PubMed Web of Science ®Google Scholar
• Suzuka K, Matsui H, Iitsuka Y, et al. Adjuvant hysterectomy in low-risk gestational trophoblastic disease. Obstet Gynecol. 2001;97(3):431–434.
   PubMed Web of Science ®Google Scholar
• Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am. 2012;26(1):111–131.
   PubMed Web of Science ®Google Scholar
• Tian Q, Xue Y, Zheng W, et al. Overexpression of hypoxia-inducible factor 1α induces migration and invasion through Notch signaling. Int J Oncol. 2015;47(2):728–738.
   PubMed Web of Science ®Google Scholar
• Zhang X, Pang W, Liu H, et al. Lidocine potentiates the cytotoxicity of 5-fluorouracil to choriocarcinoma cells by downregulating ABC transport proteins expression. J Cell Biochem. 2019;120(10):16533–16542.
   PubMed Web of Science ®Google Scholar
• Amjad MT, Kasi A. Cancer Chemotherapy. In: StatPearls. Treasure Island (FL); 2021.
   Google Scholar
• Wilcox G. Insulin and insulin resistance. Clin biochemist Rev. 2005;26(2):19–39.
   PubMedGoogle Scholar
• Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocr Rev. 1987;8(2):132–141.
   PubMed Web of Science ®Google Scholar
• Sissung TM, Schmidt KT, Figg WD. Insulin potentiation therapy for cancer?, The Lancet. Oncology 2019;20:191–192.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wen F, Dang L, et al. Insulin enhances apoptosis induced by cisplatin in human esophageal squamous cell carcinoma EC9706 cells related to inhibition of autophagy. Chinese Med J. 2014;127(2):353–358.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Wozniak M, Luc M, et al. Insulin and novel thioglycosides exert suppressive effect on human breast and colon carcinoma cells. Oncotarget. 2017;8(69):114173–114182.
   PubMedGoogle Scholar
• Martínez‐García D, Manero‐Rupérez N, Quesada R, et al. Therapeutic strategies involving survivin inhibition in cancer. Med Res Rev. 2019;39(3):887–909.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Validating survivin as a cancer therapeutic target, Nature reviews. Cancer 2003;3:46–54.
   PubMed Web of Science ®Google Scholar
• Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 2001;108(7):981–990.
   PubMed Web of Science ®Google Scholar
• Seckl MJ, Sebire NJ, Fisher RA, et al. Gestational trophoblastic disease: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi39–50.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
   PubMed Web of Science ®Google Scholar
• Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–2223.
   PubMed Web of Science ®Google Scholar
• Argirion I, Weinstein SJ, Mannisto S, et al. Glucose, Indices of Insulin Resistance, and Risk of Lung Cancer, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research. cosponsored Am Society Preventive Oncol. 2017;26:1519–1524.
   Google Scholar
• Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. Bmj. 2015;350(jan02 1):g7607.
   PubMed Web of Science ®Google Scholar
• Shlomai G, Neel B, LeRoith D, et al. Type 2 diabetes mellitus and cancer: the role of pharmacotherapy. J Clin Oncol. 2016;34(35):4261–4269.
   PubMed Web of Science ®Google Scholar
• Home P. Insulin therapy and cancer. Diabetes Care. 2013;36(Suppl Supplement_2):S240–244.
   PubMed Web of Science ®Google Scholar
• Colmers IN, Bowker SL, Tjosvold LA, et al. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab. 2012;38(6):485–506.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Luc M, Ziolkowski P, et al. Insulin-induced enhancement of MCF-7 breast cancer cell response to 5-fluorouracil and cyclophosphamide. Tumor Biology. 2019;120(6):1010428317702901.
   Google Scholar
• Zou K, Ju J-H, Xie H. Pretreatment with insulin enhances anticancer functions of 5-fluorou-racil in human esophageal and colonic cancer cells. Acta Pharmacol Sin. 2007;28(5):721–730.
   PubMed Web of Science ®Google Scholar
• Wei Z, Liang L, Junsong L, et al. The impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28. J Exp Clin Cancer Res. 2015;34(1):64.
   PubMed Web of Science ®Google Scholar
• Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6(1):a009191–a009191.
   PubMed Web of Science ®Google Scholar
• Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6(1):1–12.
   PubMed Web of Science ®Google Scholar
• Shin S, Sung B-J, Cho Y-S, et al. An Anti-apoptotic Protein Human Survivin Is a Direct Inhibitor of Caspase-3 and −7 †. Biochemistry. 2001;40(4):1117–1123.
   PubMed Web of Science ®Google Scholar
• Shiozaki A, Kataoka K, Fujimura M, et al. Survivin inhibits apoptosis in cytotrophoblasts. Placenta. 2003;24(1):65–76.
   PubMed Web of Science ®Google Scholar
• Lai YJ, Lin CI, Wang CL, et al. Expression of survivin and p53 modulates honokiol-induced apoptosis in colorectal cancer cells. J Cell Biochem. 2014;115:1888–1899.
   PubMed Web of Science ®Google Scholar
• Koike H, Nitta T, Sekine Y, et al. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin. J Cancer Res Clin Oncol. 2014;140:1705–1713.
   PubMed Web of Science ®Google Scholar